Looking at so many products that are coming through, Ryan, can you help us kind of figure out what is the best practice for trying to sort out which products may be added to the formulary and what are the steps to kind of make those crucial decisions?

Wow, that's a lot to unpack.

I mean, first of all, I think that going back to what was just said, that the centralizing aspect of our cell and gene therapy program is extremely important.

When we think of the products are so diverse in the disease states that they are being approved for now.

You know, in 2017, we had one product approved for one indication commercially that we're using for cell therapy.

And now, you know, it's roughly, I think, estimated like 10% of the phase three studies are cell and gene therapy related.

And we're expecting double digit submissions to the FDA year over year.

Ryan, did you have anything to add in terms of mitigating financial toxicity for our patients?